Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.01641/full |
| _version_ | 1818552359593181184 |
|---|---|
| author | M. Fevzi Ozkaynak Andrew L. Gilman Wendy B. London Arlene Naranjo Mitchell B. Diccianni Sheena C. Tenney Malcolm Smith Karen S. Messer Robert Seeger C. Patrick Reynolds L. Mary Smith Barry L. Shulkin Marguerite Parisi John M. Maris Julie R. Park Paul M. Sondel Alice L. Yu Alice L. Yu |
| author_facet | M. Fevzi Ozkaynak Andrew L. Gilman Wendy B. London Arlene Naranjo Mitchell B. Diccianni Sheena C. Tenney Malcolm Smith Karen S. Messer Robert Seeger C. Patrick Reynolds L. Mary Smith Barry L. Shulkin Marguerite Parisi John M. Maris Julie R. Park Paul M. Sondel Alice L. Yu Alice L. Yu |
| author_sort | M. Fevzi Ozkaynak |
| collection | DOAJ |
| first_indexed | 2024-12-12T09:12:10Z |
| format | Article |
| id | doaj.art-17b92398321047eeaf8c549f096a771f |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-12T09:12:10Z |
| publishDate | 2018-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-17b92398321047eeaf8c549f096a771f2022-12-22T00:29:28ZengFrontiers Media S.A.Frontiers in Immunology1664-32242018-07-01910.3389/fimmu.2018.01641411789Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931M. Fevzi Ozkaynak0Andrew L. Gilman1Wendy B. London2Arlene Naranjo3Mitchell B. Diccianni4Sheena C. Tenney5Malcolm Smith6Karen S. Messer7Robert Seeger8C. Patrick Reynolds9L. Mary Smith10Barry L. Shulkin11Marguerite Parisi12John M. Maris13Julie R. Park14Paul M. Sondel15Alice L. Yu16Alice L. Yu17New York Medical College, Valhalla, NY, United StatesLevine Children’s Hospital, Charlotte, NC, United StatesDana Farber Cancer Institute and Boston Children’s Hospital, Harvard Medical School, Boston, MA, United StatesChildren’s Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL, United StatesMoores Cancer Center, University of California, San Diego, La Jolla, CA, United StatesChildren’s Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL, United StatesNational Cancer Institute, Bethesda, MD, United StatesMoores Cancer Center, University of California, San Diego, La Jolla, CA, United StatesChildren’s Hospital Los Angeles, University Southern California, Los Angeles, Los Angeles, CA, United StatesTexas Tech University Health Sciences Center, Lubbock, TX, United StatesUnited Therapeutics, Silver Spring, MD, United States0St. Jude’s Children’s Research Hospital, Memphis, TN, United States1Seattle Children’s Hospital, University of Washington School of Medicine, Seattle, WA, United States2Children’s Hospital of Philadelphia, Philadelphia, PA, United States1Seattle Children’s Hospital, University of Washington School of Medicine, Seattle, WA, United States3University of Wisconsin Carbone Cancer Center, Madison, WI, United StatesMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States4Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Taoyuan, Taiwanhttps://www.frontiersin.org/article/10.3389/fimmu.2018.01641/fullneuroblastomaimmunotherapyanti-GD2 chimeric antibodycytokinessafetycytokine biomarkers |
| spellingShingle | M. Fevzi Ozkaynak Andrew L. Gilman Wendy B. London Arlene Naranjo Mitchell B. Diccianni Sheena C. Tenney Malcolm Smith Karen S. Messer Robert Seeger C. Patrick Reynolds L. Mary Smith Barry L. Shulkin Marguerite Parisi John M. Maris Julie R. Park Paul M. Sondel Alice L. Yu Alice L. Yu Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 Frontiers in Immunology neuroblastoma immunotherapy anti-GD2 chimeric antibody cytokines safety cytokine biomarkers |
| title | Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 |
| title_full | Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 |
| title_fullStr | Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 |
| title_full_unstemmed | Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 |
| title_short | Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 |
| title_sort | corrigendum a comprehensive safety trial of chimeric antibody 14 18 with gm csf il 2 and isotretinoin in high risk neuroblastoma patients following myeloablative therapy children s oncology group study anbl0931 |
| topic | neuroblastoma immunotherapy anti-GD2 chimeric antibody cytokines safety cytokine biomarkers |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2018.01641/full |
| work_keys_str_mv | AT mfevziozkaynak corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT andrewlgilman corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT wendyblondon corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT arlenenaranjo corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT mitchellbdiccianni corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT sheenactenney corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT malcolmsmith corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT karensmesser corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT robertseeger corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT cpatrickreynolds corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT lmarysmith corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT barrylshulkin corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT margueriteparisi corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT johnmmaris corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT julierpark corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT paulmsondel corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT alicelyu corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT alicelyu corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 |